Biography
Michael Retsky (Ph.D in physics from University of Chicago) made a career change from physics to cancer research. He is Editor-in-Chief of Journal of Bioavailability and Bioequivalence, on staff at Harvard School of Public Health, honorary faculty at University College London, and Prof Adj at UANL, Monterrey, Mexico. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. He is on the board of directors of the Colon Cancer Alliance and has published more than 60 papers in physics and cancer. He has a patent pending for treatment of early stage cancer.
Research Interest
Cancer research, Charged particle optics and Early detection of cancer and delayed detection of cancer.
Biography
Kenji Suzuki, Ph.D. (by Published Work; Nagoya University) worked at Hitachi Medical Corporation, Japan, Aichi Prefectural University, Japan, as a faculty member, and in Department of Radiology, University of Chicago, as Assistant Professor. In 2014, he joined Department of Electric and Computer Engineering and Medical Imaging Research Center, Illinois Institute of Technology, as Associate Professor. He published more than 300 papers (including 110 peer-reviewed journal papers). He is inventor on 30 patents (including 12 granted patents), which were licensed to several companies and commercialized. He published 10 books and 22 book chapters, and edited 12 journal special issues. He was awarded/co-awarded more than 25 grants as PI including NIH R01 and ACS. He served as the Editor of a number of leading international journals, including Pattern Recognition and Medical Physics. He served as a referee for 80 international journals, an organizer of 25 international conferences, and a program committee member of 145 international conferences. He received 25 awards.
Research Interest
Radiology
Biography
Dr. Luo been studying molecular pathology related to human malignancies in the last 23 years. Currently, he is a Professor of Pathology and Director of High Throughput Genome Center at University of Pittsburgh. In the last 13 years, Dr. Luo has been largely focusing on genetic and molecular mechanism of human prostate and hepatocellular carcinomas. In this period, his group has identified and characterized several genes that are related to prostate cancer and hepatocellular carcinoma, including SAPC, myopodin, CSR1, GPx3, ITGA7, MCM7, MT1h and GPC3. He has characterized several signaling pathways that play critical roles in prostate cancer development, including Myopodin-ILK-MCM7 inhibitory signaling, myopodin-zyxin motility inhibition pathway, CSR1-CPSF3 and CSR1-XIAP apoptotic pathways, MT1h-EHMT1 egigenomic signaling, ITGA7-HtrA2 tumor suppression pathway, GPx3-PIG3 cell death pathway, and AR-MCM7 oncogenic pathway. He proposed prostate cancer field effect in 2002. He is one of the pioneers in utilizing high throughput gene expression and genome analyses to analyze field effects in prostate cancer and liver cancer. He is also the first in using methylation array and whole genome methylation sequencing to analyze prostate cancer. Recently, Dr. Luo’s group found that patterns of copy number variants of certain specific genome loci are predictive of prostate cancer clinical outcomes, regardless tissue origin. Overall, these findings advance our understanding onhow cancer develops and behaves, and lay down the foundation for better future diagnosis and treatment of human malignancies
Research Interest
Research Interests involve identifying new tumor suppressor genes, oncogenes and tumor markers in prostate cancer and hepatocellular carcinoma using high throughput and comprehensive analyses. Subsequently, we will direct our effort to evaluate the prognostic values of these genes and markers in making early diagnosis of these malignancies and serving as drug targets for cancer prevention program. As the Director of High Throughput Genome Center, I have collaborated extensively with faculty members in the UPMC and University campuses to use high throughput genome sequencing and high throughput microarray analyses to develop tests for molecular pathology and to investigate novel mechanisms for signal transduction and identifying markers for human diseases.